Background Background An earlier trial
An earlier trial demonstrated good outcomes after1year demonstrated good outcomes after1year for patients with chronic fatigue syndrome for patients with chronic fatigue syndrome (CFS) who received an educational (CFS) who received an educational intervention designed to encourage intervention designed to encourage graded activity. graded activity.
Aims Aims To determine 2-year outcomes for
To determine 2-year outcomes for the same treated patients and the the same treated patients and the response totreatmentof patients formerly response totreatmentof patients formerly in the control condition. in the control condition.
Method Method Patients in the treatment
Patients in the treatment groups ( groups (n n¼114) were followed up at 2 114) were followed up at 2 years; 32 patients from the control group years; 32 patients from the control group were offered the intervention after1year were offered the intervention after1year and were assessed1year later. and were assessed1year later. Assessments were the self-rated Assessments were the self-rated measures used in the original trial. measures used in the original trial.
Results
Results At 2 years 63 of the treated At 2 years 63 of the treated patients (55%) no longer fulfilled trial patients (55%) no longer fulfilled trial criteria for CFS compared with 64 patients criteria for CFS compared with 64 patients (56%) at1year.Fourteen of 30 crossover (56%) at1year.Fourteen of 30 crossover patients (47%) achieved a good outcome patients (47%) achieved a good outcome at1year and seven (23%) no longer at1year and seven (23%) no longer fulfilled criteria for CFS. fulfilled criteria for CFS.
Conclusions Conclusions Benefits of the
Benefits of the intervention were maintained at 2 years. intervention were maintained at 2 years. Delaying treatment is associated with Delaying treatment is associated with reduced efficacy and required more reduced efficacy and required more intensive therapy. intensive therapy.
Declaration of interest
Declaration of interest None.
None. Funding detailed in Acknowledgements. Funding detailed in Acknowledgements.
A systematic review by Whiting A systematic review by Whiting et al et al (2001 Whiting et al et al ( ) (2001 found graded exercise and cognitivefound graded exercise and cognitivebehavioural therapy to be promising treatbehavioural therapy to be promising treatments for chronic fatigue syndrome. In a ments for chronic fatigue syndrome. In a randomised controlled trial (Powell randomised controlled trial (Powell et al et al, , 2001 ), patients received evidence-based 2001), patients received evidence-based physiological explanations for symptoms physiological explanations for symptoms to encourage self-managed graded exercise to encourage self-managed graded exercise and regulation of sleep in three different and regulation of sleep in three different dosages (defined in terms of therapist time dosages (defined in terms of therapist time and follow-up telephone contacts). At 1-and follow-up telephone contacts). At 1-year follow-up, treated patients showed sigyear follow-up, treated patients showed significantly greater improvement in measures nificantly greater improvement in measures of physical functioning, fatigue, sleep and of physical functioning, fatigue, sleep and mood compared with an untreated control mood compared with an untreated control group, but no difference was found group, but no difference was found between the different dosages. The study between the different dosages. The study reported here looked at the same patient reported here looked at the same patient groups to determine if these improvements groups to determine if these improvements were maintained after a further year, and were maintained after a further year, and whether treatment dosage affected longwhether treatment dosage affected longterm outcome. A third aspect of this study term outcome. A third aspect of this study was to assess at 1 year the outcome of was to assess at 1 year the outcome of patients who had been in the 1-year trial patients who had been in the 1-year trial control group and who then crossed over control group and who then crossed over into the educational intervention. into the educational intervention.
METHOD METHOD Participants Participants
The original trial recruited 148 patients The original trial recruited 148 patients who fulfilled the Oxford criteria for who fulfilled the Oxford criteria for chronic fatigue syndrome (Sharpe chronic fatigue syndrome (Sharpe et al et al, , 1991 ) from a chronic fatigue clinic and an 1991) from a chronic fatigue clinic and an infectious diseases out-patient clinic, and infectious diseases out-patient clinic, and who scored below 25 on the physical funcwho scored below 25 on the physical functioning sub-scale of the 36-item Short Form tioning sub-scale of the 36-item Short Form Health Survey (SF-36; Ware & SherHealth Survey (SF-36; Ware & Sherbourne, 1992) . Participants were randombourne, 1992). Participants were randomised into four groups. Patients were ised into four groups. Patients were excluded if they were having further excluded if they were having further investigations, undertaking other treatinvestigations, undertaking other treatments (with the exception of antidepressant ments (with the exception of antidepressant therapy if taken at a constant dosage for at therapy if taken at a constant dosage for at least 3 months without improvement), had least 3 months without improvement), had a psychotic disorder, somatisation disorder, a psychotic disorder, somatisation disorder, eating disorder or a history of substance eating disorder or a history of substance misuse, or were non-ambulatory. misuse, or were non-ambulatory.
Treatment interventions Treatment interventions in the original study in the original study
Patients in the control group received Patients in the control group received standard medical care comprising a medical standard medical care comprising a medical assessment and a short information booklet assessment and a short information booklet that encouraged increased activity and that encouraged increased activity and positive thinking without explanation of positive thinking without explanation of symptoms. Active intervention groups symptoms. Active intervention groups received a medical assessment followed by received a medical assessment followed by evidence-based physiological explanations evidence-based physiological explanations of symptoms that focused on physical of symptoms that focused on physical deconditioning and sleep abnormalities. A deconditioning and sleep abnormalities. A home-based graded exercise programme home-based graded exercise programme was designed collaboratively with each was designed collaboratively with each patient and individualised to suit functional patient and individualised to suit functional abilities. Once the patient was engaged in abilities. Once the patient was engaged in treatment, the role of predisposing and treatment, the role of predisposing and perpetuating psychosocial factors was disperpetuating psychosocial factors was discussed. The treatment rationale was cussed. The treatment rationale was supported by a comprehensive educational supported by a comprehensive educational information pack which reiterated the information pack which reiterated the verbal explanations offered. verbal explanations offered.
Three dosages of treatment were comThree dosages of treatment were compared. Patients in the minimum interpared. Patients in the minimum intervention group received two individual vention group received two individual face-to-face sessions and monitored access face-to-face sessions and monitored access to a telephone helpline that was reported to a telephone helpline that was reported with the trial; the telephone intervention with the trial; the telephone intervention group received an additional seven planned group received an additional seven planned follow-up telephone calls; and the maxifollow-up telephone calls; and the maximum intervention group received the mum intervention group received the minimum intervention plus an additional minimum intervention plus an additional seven face-to-face treatment sessions. These seven face-to-face treatment sessions. These sessions were used to reiterate the treatsessions were used to reiterate the treatment rationale, discuss problems associated ment rationale, discuss problems associated with graded exercise using motivational inwith graded exercise using motivational interviewing techniques (Miller & Rollnick, terviewing techniques (Miller & Rollnick, 1991) and explore any relevant psycho-1991) and explore any relevant psychosocial factors. Self-reporting validated outsocial factors. Self-reporting validated outcome measures were sent by post to the come measures were sent by post to the participants before randomisation, and 3 participants before randomisation, and 3 months, 6 months and 12 months after months, 6 months and 12 months after the start of treatment. the start of treatment.
Further assessments Further assessments and interventions in this study and interventions in this study
For those who completed the treatment, a For those who completed the treatment, a 2-year assessment of outcome was con-2-year assessment of outcome was conducted using the same self-rated validated ducted using the same self-rated validated questionnaires used in the original study. questionnaires used in the original study. Patients in the original control group were Patients in the original control group were offered a similar educational intervention offered a similar educational intervention at the end of the 1-year trial period. This at the end of the 1-year trial period. This was delivered by the same therapist (P.P.) was delivered by the same therapist (P.P.) who had treated the patients in the original who had treated the patients in the original experimental groups. The former control experimental groups. The former control group patients were not given a further group patients were not given a further medical assessment before participating in medical assessment before participating in active treatment, which was a combination active treatment, which was a combination of telephone and face-to-face sessions of telephone and face-to-face sessions similar to those offered to treatment similar to those offered to treatment patients in the original trial. The number patients in the original trial. The number of sessions was determined pragmatically of sessions was determined pragmatically on the basis of patient need and was on the basis of patient need and was allowed to exceed those given to the origiallowed to exceed those given to the original treatment groups. Patients' 1-year nal treatment groups. Patients' 1-year control outcome assessments were used as control outcome assessments were used as their pre-treatment baseline measures. their pre-treatment baseline measures. These measures were reassessed 1 year after These measures were reassessed 1 year after the start of treatment. the start of treatment.
Assessments Assessments
Primary outcomes were measured on the Primary outcomes were measured on the physical functioning sub-scale of the SFphysical functioning sub-scale of the SF-36 (range 10 to 30, where 10 indicates 36 (range 10 to 30, where 10 indicates maximum physical limitation including maximum physical limitation including self-care, and 30 indicates ability to do self-care, and 30 indicates ability to do vigorous sports) and the fatigue scale vigorous sports) and the fatigue scale (Chalder (Chalder et al et al, 1993; range 0-11, scores , 1993 ; range 0-11, scores over 3 indicate excessive fatigue). The preover 3 indicate excessive fatigue). The predetermined criterion of clinically significant determined criterion of clinically significant improvement was a score of 25 or over or improvement was a score of 25 or over or an increase of 10 or more in the baseline an increase of 10 or more in the baseline score on the physical functioning sub-scale score on the physical functioning sub-scale of the SF-36. This is virtually equivalent of the SF-36. This is virtually equivalent to normal daily functioning for the UK to normal daily functioning for the UK general population (Garratt general population (Garratt et al et al, 1993) . , 1993). The intention-to-treat mean score for phyThe intention-to-treat mean score for physical functioning of the educational intersical functioning of the educational intervention patients at 1 year was 24.74. The vention patients at 1 year was 24.74. The comparable mean physical functioning comparable mean physical functioning score for the control group, used as a basescore for the control group, used as a baseline measure before crossover into active line measure before crossover into active treatment, was 16.94. treatment, was 16.94.
Secondary outcome measures adminiSecondary outcome measures administered to both groups at the same time stered to both groups at the same time points included the Hospital Anxiety and points included the Hospital Anxiety and Depression (HAD) scale (Zigmond & Depression (HAD) scale (Zigmond & Snaith, 1983 ; scores above 10 indicate caseSnaith, 1983; scores above 10 indicate caseness on each of the anxiety and depression ness on each of the anxiety and depression sub-scales); a four-item sleep problem sub-scales); a four-item sleep problem questionnaire (Jenkins questionnaire (Jenkins et al et al, 1988; range , 1988 ; range 0-20, where 0 indicates no sleep problems 0-20, where 0 indicates no sleep problems and 20 indicates maximum sleep and 20 indicates maximum sleep problems); and a seven-point global impresproblems); and a seven-point global impression of change score taken 1 year from trial sion of change score taken 1 year from trial entry and ranging from 'very much better' entry and ranging from 'very much better' to 'very much worse ' (Guy, 1976) . to 'very much worse ' (Guy, 1976) .
Statistical analysis Statistical analysis
Analyses of the outcome data from both the Analyses of the outcome data from both the 2-year assessment group and the crossover 2-year assessment group and the crossover control group were carried out separately. control group were carried out separately. In each case we used an intention-to-treat In each case we used an intention-to-treat analysis and included all patients who were analysis and included all patients who were randomised into the original trial. Crossrandomised into the original trial. Crossover analysis included all who accepted over analysis included all who accepted crossover treatment. crossover treatment.
RESULTS RESULTS

Patient recruitment Patient recruitment
During the original trial, 19 patients from During the original trial, 19 patients from the active intervention groups were lost to the active intervention groups were lost to follow-up (Powell follow-up (Powell et al et al, 2001 ); a further , 2001); a further five patients were lost to follow-up at 2 five patients were lost to follow-up at 2 years (two developed other medical condiyears (two developed other medical conditions, one died by suicide and two were tions, one died by suicide and two were untraceable). The last values obtained from untraceable). The last values obtained from these patients were carried forward. Thirtythese patients were carried forward. Thirtytwo patients in the control group completed two patients in the control group completed the original trial and were subsequently the original trial and were subsequently offered active treatment: 30 patients offered active treatment: 30 patients accepted. Five patients withdrew from accepted. Five patients withdrew from treatment: one for medical reasons and treatment: one for medical reasons and four who could not comply with the four who could not comply with the intervention. The last outcome values intervention. The last outcome values obtained from these treatments were also obtained from these treatments were also carried forward. carried forward.
The median number of telephone and The median number of telephone and face-to-face treatment sessions in the face-to-face treatment sessions in the crossover intervention was 16 (minimum crossover intervention was 16 (minimum 1, maximum 36). The mean duration of 1, maximum 36). The mean duration of treatment was 40.8 weeks (minimum 1 treatment was 40.8 weeks (minimum 1 week, maximum 1 year). week, maximum 1 year).
Two-year outcome of original Two-year outcome of original intervention patients intervention patients Table 1 and Fig. 1 show the outcome Table 1 and Fig. 1 show the outcome measures at the original trial baseline measures at the original trial baseline assessment and at 1-year and 2-year assessment and at 1-year and 2-year follow-up. Repeated-measures analysis of follow-up. Repeated-measures analysis of variance (ANOVA) was used to compare variance (ANOVA) was used to compare the three treatment groups at each point. the three treatment groups at each point. For physical functioning scores, there was For physical functioning scores, there was no significant difference between the no significant difference between the treatment groups ( treatment groups (F F 2,111 2,111 ¼0.47, 0.47, P P¼0.63) 0.63) 14 3 14 3 and the group and the group6 6treatment interaction treatment interaction was also non-significant ( was also non-significant (F F 4,222 4,222 ¼9.55, 9.55, P P¼0.51). However, there was a highly 0.51). However, there was a highly significant difference between scores at significant difference between scores at the three time points ( the three time points (F F 2,222 2,222 ¼248.58, 248.58, P P5 50.001). Bonferroni tests confirmed that 0.001). Bonferroni tests confirmed that there was no significant difference between there was no significant difference between scores at 1 year and 2 years, but that scores at 1 year and 2 years, but that scores at both time points were improved scores at both time points were improved compared with baseline ( compared with baseline (P P5 50.001 for 0.001 for each comparison). each comparison).
For fatigue scores an identical pattern For fatigue scores an identical pattern was observed, with a significant effect for was observed, with a significant effect for time points ( time points (F F 2,222 2,222 ¼227.30, 227.30, P P5 50.001) but 0.001) but no significant group effect ( no significant group effect (F F 2,111 2,111 ¼0.45, 0.45, P P¼0.64) or interaction ( 0.64) or interaction (F F 4,222 4,222 ¼8.34, 8.34, P P¼0.36). Again, scores at both follow-up 0.36). Again, scores at both follow-up points were improved compared with points were improved compared with those at baseline ( those at baseline (P P5 50.001 for each com-0.001 for each comparison) but there was no significant differparison) but there was no significant difference between scores at the two follow-up ence between scores at the two follow-up points. points. Table 2 shows the number of patients Table 2 shows the number of patients from the different educational interventions from the different educational interventions who achieved a clinically significant outwho achieved a clinically significant outcome and/or no longer fulfilled trial criteria come and/or no longer fulfilled trial criteria for the condition at the 1-year and 2-year for the condition at the 1-year and 2-year follow-up assessments. On the clinical follow-up assessments. On the clinical global impression scale, 70 of 90 global impression scale, 70 of 90 patients (78%) who completed the educapatients (78%) who completed the educational intervention reported being 'very tional intervention reported being 'very much better' or 'much better' at 2 years much better' or 'much better' at 2 years compared with 80 of 95 (84%) at 1 year. compared with 80 of 95 (84%) at 1 year.
Outcome of former control Outcome of former control patients after 1 year of active patients after 1 year of active treatment treatment Table 3 and Fig. 1 show the outcome Table 3 and Fig. 1 show the outcome measures at the pre-treatment assessment measures at the pre-treatment assessment and 1-year follow-up for patients who and 1-year follow-up for patients who crossed over into active treatment. crossed over into active treatment. Repeated-measures ANOVA was used to Repeated-measures ANOVA was used to compare the patients at baseline during compare the patients at baseline during the original trial, the pre-treatment assessthe original trial, the pre-treatment assessment at the end of the control period, and ment at the end of the control period, and 1 year after the end of treatment. On the 1 year after the end of treatment. On the physical functioning scale, a significant physical functioning scale, a significant effect was found for time ( effect was found for time (F F 2,58 2,58 ¼23.65, 23.65, P P5 50.001). Bonferroni tests revealed that 0.001). Bonferroni tests revealed that this was accounted for by significant differthis was accounted for by significant differences between scores after treatment and ences between scores after treatment and at both pre-treatment assessments at both pre-treatment assessments ( (P P5 50.001 for each comparison) but that 0.001 for each comparison) but that there was no significant difference bethere was no significant difference between scores at the original trial baseline tween scores at the original trial baseline and pre-treatment assessments. A similar and pre-treatment assessments. A similar pattern was observed pattern was observed in the fatigue scores in the fatigue scores of these patients, with a significant effect of these patients, with a significant effect for time ( for time (F F 2,58 2,58 ¼22.76, 22.76, P P5 50.001) accounted 0.001) accounted for entirely by differences between scores at for entirely by differences between scores at the final follow-up point and both prethe final follow-up point and both pretreatment assessments ( treatment assessments (P P5 50.001 for each 0.001 for each comparison). At the end of treatment, comparison). At the end of treatment, almost a half of the crossover patients almost a half of the crossover patients (14 out of 30; 47%) achieved a clinically (14 out of 30; 47%) achieved a clinically significant outcome; almost a quarter no significant outcome; almost a quarter no longer fulfilled the trial criteria for longer fulfilled the trial criteria for chronic fatigue syndrome (7 out of 30; chronic fatigue syndrome (7 out of 30; 23%); and more than two-thirds of those 23%); and more than two-thirds of those who completed the educational interwho completed the educational intervention (17 out of 25; 68%) reported vention (17 out of 25; 68%) reported being 'very much better' or 'much better' being 'very much better' or 'much better' on the global assessment of outcome. on the global assessment of outcome.
Comparison of outcomes between
Comparison of outcomes between the original treatment groups and the original treatment groups and the crossover group the crossover group To assess the relative responsiveness to To assess the relative responsiveness to treatment of the control group compared treatment of the control group compared with the original treatment groups, onewith the original treatment groups, oneway ANOVAs were calculated for the way ANOVAs were calculated for the primary assessment measures taken from primary assessment measures taken from each group 1 year after their treatment each group 1 year after their treatment had commenced (which was 1 year after had commenced (which was 1 year after inception in the case of the originally inception in the case of the originally treated groups and 2 years after inception treated groups and 2 years after inception for the control group). In the case of for the control group). In the case of physical functioning scores, no difference physical functioning scores, no difference was observed between the groups was observed between the groups ( (F F 3,140 3,140 ¼1.49, 1.49, P P¼0.22). However, a signifi-0.22). However, a significant difference was observed for fatigue cant difference was observed for fatigue scores ( scores (F F 3,140 3,140 ¼3.41, 3.41, P P5 50.02) which was 0.02) which was accounted for by better scores in the miniaccounted for by better scores in the minimum and maximum original treatment mum and maximum original treatment groups (Bonferroni groups (Bonferroni P P5 50.05 for each 0.05 for each comparison) compared with the crossover comparison) compared with the crossover patients. There was a significant difference patients. There was a significant difference between the number of patients who no between the number of patients who no longer met the trial criteria for chronic fatilonger met the trial criteria for chronic fatigue syndrome ( gue syndrome (w w 2 2 ¼10.25, 10.25, P P5 50.02), but no 0.02), but no significant difference was observed in the significant difference was observed in the proportion of patients achieving a clinically proportion of patients achieving a clinically significant outcome ( significant outcome (w w 2 2 ¼5.37, 5.37, P P¼0.15). 0.15).
DISCUSSION DISCUSSION
Maintenance of gains at 2-year Maintenance of gains at 2-year follow-up follow-up
Patients who had received evidence-based Patients who had received evidence-based physiological explanations for the physiological explanations for the symptoms of chronic fatigue syndrome to symptoms of chronic fatigue syndrome to encourage graded exercise and regulate encourage graded exercise and regulate sleep maintained improvements at 2 years. sleep maintained improvements at 2 years. Despite apparent trends across most meaDespite apparent trends across most measures for a slight worsening of outcome in sures for a slight worsening of outcome in the minimum intervention group and, if the minimum intervention group and, if anything, a slight further improvement in anything, a slight further improvement in the maximum intervention group, none of the maximum intervention group, none of these differences approached significance. these differences approached significance. One patient who had received treatment One patient who had received treatment died by suicide in the extended follow-up died by suicide in the extended follow-up period. It seems unlikely that this was an period. It seems unlikely that this was an adverse reaction to the treatment proadverse reaction to the treatment programme. At the original 1-year follow-up gramme. At the original 1-year follow-up point this patient had made no improvepoint this patient had made no improvement on any of the main outcome measures ment on any of the main outcome measures line at 12 months indicates the point at which patients in the control group crossed over into active treatment. line at 12 months indicates the point at which patients in the control group crossed over into active treatment.
The horizontal reference line indicates the mean physical functioning score for the UK general population The horizontal reference line indicates the mean physical functioning score for the UK general population (Garratt (Garratt et al et al, 1993) . , 1993).
and was showing evidence of serious affecand was showing evidence of serious affective symptoms. Prior to killing himself he tive symptoms. Prior to killing himself he was under psychiatric care. was under psychiatric care.
Follow-up of control patients Follow-up of control patients after 1 year of active treatment after 1 year of active treatment
Patients who had been in the no-treatment Patients who had been in the no-treatment control group for 1 year and then crossed control group for 1 year and then crossed over into active treatment were judged by over into active treatment were judged by the therapist to require more sessions over the therapist to require more sessions over a longer period. Although this could be seen a longer period. Although this could be seen as evidence that treatment was harder to as evidence that treatment was harder to implement following a delay, the treatimplement following a delay, the treatments delivered in the original treatment ments delivered in the original treatment arms were constrained in length, and it is arms were constrained in length, and it is possible that the therapist would have possible that the therapist would have chosen to extend these interventions if chosen to extend these interventions if allowed to do so. However, there was allowed to do so. However, there was evidence that the crossover patients showed evidence that the crossover patients showed less response on the measure of fatigue than less response on the measure of fatigue than the originally treated patients and were also the originally treated patients and were also less likely to recover as defined by the trial less likely to recover as defined by the trial criteria for chronic fatigue. Although we criteria for chronic fatigue. Although we found no relationship between duration of found no relationship between duration of illness and outcome in our previous analysis illness and outcome in our previous analysis of the 1-year follow-up data (Bentall of the 1-year follow-up data (Bentall et al et al, , 2002) , others have found an association 2002), others have found an association between these variables (Clark between these variables (Clark et al et al, 1995; , 1995; Vercoulen Vercoulen et al et al, 1996) . Therefore, the , 1996). Therefore, the possible relative unresponsiveness of the possible relative unresponsiveness of the crossover patients might be due to the duracrossover patients might be due to the duration of illness, or the psychological effects tion of illness, or the psychological effects of being placed in a waiting group. of being placed in a waiting group.
Consistency with previous findings Consistency with previous findings
Our findings support the long-term efficacy Our findings support the long-term efficacy of treatments for chronic fatigue syndrome of treatments for chronic fatigue syndrome that incorporate graded exercise, including that incorporate graded exercise, including cognitive-behavioural therapy (Bonner cognitive-behavioural therapy (Bonner et et al al, 1994; Deale , 1994; Deale et al et al, 2001) . The effective-, 2001). The effectiveness of such treatments may reflect the ness of such treatments may reflect the way in which they directly address physioway in which they directly address physiological factors that can perpetuate the logical factors that can perpetuate the condition. Although there is no evidence condition. Although there is no evidence of consistent pathological changes in of consistent pathological changes in chronic fatigue syndrome, there is evidence chronic fatigue syndrome, there is evidence of a disturbance in bodily functioning of a disturbance in bodily functioning involving cardiovascular and muscular deinvolving cardiovascular and muscular deconditioning (Edwards conditioning (Edwards et al et al, 1994; De Lor-, 1994; De Lorenzo enzo et al et al, 1998) . There is also evidence of , 1998). There is also evidence of sleep abnormalities (Morriss sleep abnormalities (Morriss et al et al, 1997) , , 1997), mild cortisol deficiency (Demitrack mild cortisol deficiency (Demitrack et al et al, , 1991) and desynchronisation of circadian 1991) and desynchronisation of circadian rhythms (Williams rhythms (Williams et al et al, 1996 (Williams et al et al, ) in patients , 1996 in patients with the syndrome. In the absence of an with the syndrome. In the absence of an appropriate explanation, the subsequent appropriate explanation, the subsequent symptoms can be misinterpreted as signs symptoms can be misinterpreted as signs of an underlying pathological condition of an underlying pathological condition leading to reduced activity and chaotic leading to reduced activity and chaotic sleep patterns, which perpetuate the synsleep patterns, which perpetuate the syndrome. Our finding that the provision of drome. Our finding that the provision of physiological explanations for symptoms physiological explanations for symptoms is associated with improved patient outis associated with improved patient outcome is consistent with previous research. come is consistent with previous research. Patients have a basic physical conception Patients have a basic physical conception of the body and its functions (Mabeck & of the body and its functions (Mabeck & Olesen, 1997) ; consequently, physical Olesen, 1997); consequently, physical explanations for the causal mechanism of explanations for the causal mechanism of symptoms can lead to reattribution and symptoms can lead to reattribution and are empowering in the self-management of are empowering in the self-management of illness (Salmon illness (Salmon et al et al, 1999) . Indeed, the vast , 1999). Indeed, the vast majority of patients who completed treatmajority of patients who completed treatment in the original trial (Powell ment in the original trial (Powell et al et al, , 2001) reported that the physical explana-2001) reported that the physical explanations convinced them to carry out graded tions convinced them to carry out graded exercise and regulate chaotic sleep patterns; exercise and regulate chaotic sleep patterns; furthermore, they reported that they would furthermore, they reported that they would recommend an educational intervention recommend an educational intervention to other people with chronic fatigue to other people with chronic fatigue syndrome. syndrome.
Limitations of this study Limitations of this study
This study has several limitations. Patients This study has several limitations. Patients who withdrew from treatment in the who withdrew from treatment in the original trial were not followed up and, original trial were not followed up and, although in the analysis their last values although in the analysis their last values were carried forward, it would have been were carried forward, it would have been better if we had been able to obtain better if we had been able to obtain patients' actual outcome scores. There was patients' actual outcome scores. There was no control comparison for 2-year followno control comparison for 2-year followup of the treated patients. However, in view up of the treated patients. However, in view of the reduced efficacy of treatment when of the reduced efficacy of treatment when delivered after a 1-year wait, it would have delivered after a 1-year wait, it would have been neither desirable nor ethically possible been neither desirable nor ethically possible to justify a 2-year control period without to justify a 2-year control period without treatment. Patient outcome was assessed treatment. Patient outcome was assessed by self-report measures, and it would have by self-report measures, and it would have been helpful in addition to use objective been helpful in addition to use objective measures of physiological exercise. measures of physiological exercise. Although the comparison of the crossover Although the comparison of the crossover patient group with the original treatment patient group with the original treatment group involved confounded time points, it group involved confounded time points, it is unlikely that this could explain the is unlikely that this could explain the findings. No economic analysis was findings. No economic analysis was performed. performed.
14 5 14 5 Table 3  Table 3 Outcome measures at the pre-treatment Outcome measures at the pre-treatment assesment and at 1-year follow-up for patients who assesment and at 1-year follow-up for patients who crossed over into active treatment ( crossed over into active treatment (n n¼30) 30)
Outcome Delay in treatment is associated with reduced treatment efficacy.
& & It is possible that patients placed in waiting-list control groups are adversely It is possible that patients placed in waiting-list control groups are adversely affected by being assigned to this condition.This effect could bias clinical trial results affected by being assigned to this condition.This effect could bias clinical trial results and needs to be studied in more detail. and needs to be studied in more detail.
LIMITATIONS LIMITATIONS
& & Patients who withdrew from treatment in the original trial were not followed up.
Patients who withdrew from treatment in the original trial were not followed up. 
